Newer products like cardiology drug Repatha and immunology drug Tezspire (approved in December 2021) are poised to be top products by 2030, in addition to Lumakras (approved in May 2021).

Last Updated: Aug. 29, 2023 at 3:22 p.m. ET First Published: Aug. 29, 2023 at 7:50 a.m. ET ...

Much of the boost can be attributed to sales of products acquired in Amgen’s $27.8 billion buyout of Horizon Therapeutics, which was completed early in the fourth quarter of last year. Assets ...

Amgen Inc. said it had agreed to sell two of its smaller drugs and license a third to Swedish drugmaker Biovitrum AB in a deal valued at $130 million.

WASHINGTON, Dec. 15, 2020 /PRNewswire/ -- The American College of Cardiology, in collaboration with Amgen and Veradigm, today announced a new nati ...

WASHINGTON—The Federal Trade Commission said Friday it had agreed to end its legal challenge of drugmaker Amgen ’s AMGN 0.60% $27.8 billion deal to buy Horizon Therapeutics, averting a trial ...

“In our opinion, Amgen’s fundamentals have never been stronger,” said Wang, who has a $100 12-month target price for Amgen shares, which were trading around $80 on Dec. 6.

For the full year, Amgen narrowed its outlook for adjusted earnings per share to a range of $17.25 to $17.85 on revenue of $26 billion to $26.3 billion, from its previous forecast of $17 to $18 ...